ArisGlobal, a provider of solutions to the life science industry, has announced the immediate availability of agEncoder 2.1, its comprehensive coding and dictionary management system.
The new release, certified by the Uppsala Monitoring Center to utilize the full features of WHO DRUG dictionary, offers new capabilities such as multi-lingual MedDRA support (including English, French, German, Italian, Japanese, Spanish, Portuguese, Czech, Hungarian and Dutch). agEncoder also extends support of standardized MedDRA Queries (SMQs) and Custom MedDRA Queries (CMQs) including improved search capabilities and full impact analysis of new MedDRA versions.
Integrated with ArisGlobal’s pharmacovigilance and safety system (ARISg) and the company’s electronic data capture technology (agCapture), agEncoder offers comprehensive dictionary management and centralized coding with integrated workflow to ensure accurate and consistent coding of clinical terms. Further functionality enhancements include improved search capability of the WHO-DD browser (e.g. search for active ingredients, search for preferred terms, generic terms, drug synonyms and umbrella search) and the use of eSignature.
Commented Mathias Poensgen, product manager. “agEncoder 2.1 serves the coding needs of both pharmacovigilance and clinical teams to improve the quality as well as the efficiency of their coding process.”
agEncoder 2.1 will be available to customers as a licensed, on-premise solution or as a hosted solution via agOnDemand™, ArisGlobal's comprehensive Software-as-a-Service (SaaS) delivery platform.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.